Merus N.V. (MRUS) Prices 3.86M Share Offering at $28.50/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Merus N.V. (MRUS) Announces Proposed Stock Offering, Size not Disclosed
November 4, 2021 4:09 PM EDTMerus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the launch of a proposed underwritten public offering of its common shares (the Offer Shares). All of the common shares are being offered by Merus. In addition, Merus expects to grant the underwriters a 30-day option to purchase an additional 15% of the Offer Shares (the Option Shares and together with the Offer Shares, the Shares). The offering is subject to market conditions and other closing conditions, and there can be no assurance as to whether or... More
Merus N.V. (MRUS) PT Raised to $33 at RBC Capital
November 3, 2021 6:12 AM EDTRBC Capital analyst Brian Abrahams raised the price target on Merus N.V. (NASDAQ: MRUS) to $33.00 (from $21.00) while maintaining a Sector Perform rating.... More
